stockrow
Saturday 7 November 2026
Export MREO’s income statement to Excel — free account
Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023.
- EPS
- +52.3%
- Free cash flow
- +21.0%
Quarter to June 2026, against a year earlier
0.28
0.00
0.00%
Follow MREO
Alert me
Mereo BioPharma Group plc - Sponsored ADR (MREO) P/E ratio
Mereo BioPharma Group plc - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Dec 2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| BMEA Biomea Fusion, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| IMA ImageneBio, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| TIL Instil Bio, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)